Towards effective and safe thrombolysis and thromboprophylaxis: Preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets

Circulation Research

Volumn 114, Issue 7, 2014, Pages 1083-1093

  Wang, Xiaowei ^a   Palasubramaniam, Jathushan ^a   Gkanatsas, Yannik ^a   Hohmann, Jan David ^a   Westein, Erik ^a   Kanojia, Ruchi ^a   Alt, Karen ^a   Huang, Dexing ^a   Jia, Fu ^a   Ahrens, Ingo ^a,b   Medcalf, Robert L ^c   Peter, Karlheinz ^a,c   Hagemeyer, Christoph E ^a,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF FREIBURG   (Germany)

^c MONASH UNIVERSITY   (Australia)

Author keywords

blood platelets; thrombolytic therapy; thrombosis; urokinase type plasminogen activator

Indexed keywords

FERRIC CHLORIDE; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HYBRID PROTEIN; PROUROKINASE; RECOMBINANT ANTIBODY; SODIUM CHLORIDE; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; BLOOD FLOW; BODY WEIGHT; CAROTID ARTERY OBSTRUCTION; CONTROLLED STUDY; DRUG MEGADOSE; DRUG TARGETING; FERRIC CHLORIDE INJURY; IN VITRO STUDY; IN VIVO STUDY; INJURY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REAL TIME ECHOGRAPHY; THROMBOCYTE ACTIVATION; THROMBOPROPHYLAXIS; THROMBUS;

BLOOD PLATELETS; THROMBOLYTIC THERAPY; THROMBOSIS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

ANIMALS; BLOOD PLATELETS; CAROTID ARTERIES; CHO CELLS; CRICETINAE; CRICETULUS; DRUG EVALUATION, PRECLINICAL; FIBRINOLYTIC AGENTS; INTEGRIN ALPHA2; MICE; MICE, INBRED C57BL; PLASMINOGEN; PLATELET ACTIVATION; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; THROMBOEMBOLISM; THROMBOLYTIC THERAPY; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84897567751     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.114.302514     Document Type: Article

References (46)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-e245.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
3. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451:914-918.
4. Collen D, Lijnen HR. The tissue-type plasminogen activator story. Arterioscler Thromb Vasc Biol. 2009;29:1151-1155.
5. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med. 1998;4:228-231.
6. Donnan GA, Davis SM, Parsons MW, Ma H, Dewey HM, Howells DW. How to make better use of thrombolytic therapy in acute ischemic stroke. Nat Rev Neurol. 2011;7:400-409.
7. Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation. 1999;99:3050-3055.
8. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet. 1999;353:227-231.
9. Hagemeyer CE, Peter K. Targeting the platelet integrin GPIIb/IIIa. Curr Pharm Des. 2010;16:4119-4133.
10. Armstrong PC, Peter K. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again. Thromb Haemost. 2012;107:808-814.
11. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
12. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001;357:1915-1924.
13. Peter K, Schwarz M, Ylänne J, Kohler B, Moser M, Nordt T, Salbach P, Kübler W, Bode C. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood. 1998;92:3240-3249.
14. Schwarz M, Katagiri Y, Kotani M, Bassler N, Loeffler C, Bode C, Peter K. Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61). J Pharmacol Exp Ther. 2004;308:1002-1011.
15. Schwarz M, Meade G, Stoll P, Ylanne J, Bassler N, Chen YC, Hagemeyer CE, Ahrens I, Moran N, Kenny D, Fitzgerald D, Bode C, Peter K. Conformationspecific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circ Res. 2006;99:25-33.
16. Schwarz M, Röttgen P, Takada Y, Le Gall F, Knackmuss S, Bassler N, Büttner C, Little M, Bode C, Peter K. Single-chain antibodies for the conformation-specific blockade of activated platelet integrin alphaIIbbeta3 designed by subtractive selection from naive human phage libraries. FASEB J. 2004;18:1704-1706.
17. von zur Muhlen C, Sibson NR, Peter K, Campbell SJ, Wilainam P, Grau GE, Bode C, Choudhury RP, Anthony DC. A contrast agent recognizing activated platelets reveals murine cerebral malaria pathology undetectable by conventional MRI. J Clin Invest. 2008;118:1198-1207.
18. von zur Muhlen C, von Elverfeldt D, Moeller JA, Choudhury RP, Paul D, Hagemeyer CE, Olschewski M, Becker A, Neudorfer I, Bassler N, Schwarz M, Bode C, Peter K. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation. 2008;118:258-267.
19. Wang X, Hagemeyer CE, Hohmann JD, Leitner E, Armstrong PC, Jia F, Olschewski M, Needles A, Peter K, Ahrens I. Novel single-chain antibody-targeted microbubbles for molecular ultrasound imaging of thrombosis: validation of a unique noninvasive method for rapid and sensitive detection of thrombi and monitoring of success or failure of thrombolysis in mice. Circulation. 2012;125:3117-3126.
20. Granelli-Piperno A, Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med. 1978;148:223-234.
21. Vassalli JD, Belin D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett. 1987;214:187-191.
22. Stoll P, Bassler N, Hagemeyer CE, Eisenhardt SU, Chen YC, Schmidt R, Schwarz M, Ahrens I, Katagiri Y, Pannen B, Bode C, Peter K. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation. Arterioscler Thromb Vasc Biol. 2007;27:1206-1212.
23. Hohmann JD, Wang X, Krajewski S, Selan C, Haller CA, Straub A, Chaikof EL, Nandurkar HH, Hagemeyer CE, Peter K. Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding? Blood. 2013;121:3067-3075.
24. Stein PD, Matta F. Acute pulmonary embolism. Curr Probl Cardiol. 2010;35:314-376.
25. Samson AL, Medcalf RL. Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity. Neuron. 2006;50:673-678.
26. Marder VJ. Historical perspective and future direction of thrombolysis research: the re-discovery of plasmin. J Thromb Haemost. 2011;9(suppl 1):364-373.
27. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001;357:1905-1914.
28. Runge MS, Bode C, Matsueda GR, Haber E. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo. Proc Natl Acad Sci USA. 1987;84:7659-7662.
29. Peter K, Graeber J, Kipriyanov S, Zewe-Welschof M, Runge MS, Kübler W, Little M, Bode C. Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa. Circulation. 2000;101:1158-1164.
30. Sakharov DV, Rijken DC. Superficial accumulation of plasminogen during plasma clot lysis. Circulation. 1995;92:1883-1890.
31. Dewerchin M, Lijnen HR, Stassen JM, De Cock F, Quertermous T, Ginsberg MH, Plow EF, Collen D. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo. Blood. 1991;78:1005-1018.
32. Calvete JJ. Platelet integrin GPIIb/IIIa: structure-function correlations. An update and lessons from other integrins. Proc Soc Exp Biol Med. 1999;222:29-38.
33. Bode C, Meinhardt G, Runge MS, Freitag M, Nordt T, Arens M, Newell JB, Kübler W, Haber E. Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation. Circulation. 1991;84:805-813.
34. Hagemeyer CE, von zur Muhlen C, von Elverfeldt D, Peter K. Single-chain antibodies as diagnostic tools and therapeutic agents. Thromb Haemost. 2009;101:1012-1019.
35. Hagemeyer CE, Schwarz M, Peter K. Single-chain antibodies as new antithrombotic drugs. Semin Thromb Hemost. 2007;33:185-195.
36. Martínez-Sánchez P, Díez-Tejedor E, Fuentes B, Ortega-Casarrubios MA, Hacke W. Systemic reperfusion therapy in acute ischemic stroke. Cerebrovasc Dis. 2007;24(suppl 1):143-152.
37. von Kummer R, Albers GW, Mori E; DIAS Steering Committees. The Desmoteplase in Acute Ischemic Stroke (DIAS) clinical trial program. Int J Stroke. 2012;7:589-596.
38. Medcalf RL. Desmoteplase: discovery, insights and opportunities for ischaemic stroke. Br J Pharmacol. 2012;165:75-89.
39. Holvoet P, Laroche Y, Lijnen HR, van Cauwenberge R, Demarsin E, Brouwers E, Matthyssens G, Collen D. Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase. J Biol Chem. 1991;266:19717-19724.
40. Ding BS, Hong N, Murciano JC, Ganguly K, Gottstein C, Christofidou-Solomidou M, Albelda SM, Fisher AB, Cines DB, Muzykantov VR. Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood. 2008;111:1999-2006.
41. Chacko AM, Nayak M, Greineder CF, Delisser HM, Muzykantov VR. Collaborative enhancement of antibody binding to distinct PECAM-1 epitopes modulates endothelial targeting. PLoS One. 2012;7:e34958.
42. Zaitsev S, Spitzer D, Murciano JC, Ding BS, Tliba S, Kowalska MA, Marcos-Contreras OA, Kuo A, Stepanova V, Atkinson JP, Poncz M, Cines DB, Muzykantov VR. Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood. 2010;115:5241-5248.
43. Ding BS, Gottstein C, Grunow A, Kuo A, Ganguly K, Albelda SM, Cines DB, Muzykantov VR. Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. Blood. 2005;106:4191-4198.
44. Danielyan K, Ding BS, Gottstein C, Cines DB, Muzykantov VR. Delivery of anti-platelet-endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema. J Pharmacol Exp Ther. 2007;321:947-952.
45. Hagemeyer CE, Tomic I, Weirich U, Graeber J, Nordt T, Runge MS, Bode C, Peter K. Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase. J Thromb Haemost. 2004;2:797-803.
46. Kivitz A, Segurado OG. HUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab. Expert Rev Med Devices. 2007;4:109-116.